AN2 Therapeutics Inc (NASDAQ:ANTX) shares, rose in value on Wednesday, June 18, with the stock price down by -6.78% to the previous day’s close as strong demand from buyers drove the stock to $1.10.
Actively observing the price movement in the last trading, the stock closed the session at $1.18, falling within a range of $1.1 and $1.1834. The value of beta (5-year monthly) was -0.082. Referring to stock’s 52-week performance, its high was $3.07, and the low was $0.87. On the whole, ANTX has fluctuated by -7.56% over the past month.
With the market capitalization of AN2 Therapeutics Inc currently standing at about $33.20 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ANTX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of ANTX currently trading nearly -2.44% and -7.76% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 45.06, while the 7-day volatility ratio is showing 7.22% which for the 30-day chart, stands at 4.60%. Furthermore, AN2 Therapeutics Inc (ANTX)’s beta value is -0.08, and its average true range (ATR) is 0.07.
A comparison of AN2 Therapeutics Inc (ANTX) with its peers suggests the former has fared considerably weaker in the market. ANTX showed an intraday change of -6.78% in last session, and over the past year, it shrunk by -49.31%%.
Data on historical trading for AN2 Therapeutics Inc (NASDAQ:ANTX) indicates that the trading volumes over the past 10 days have averaged 0.45 and over the past 3 months, they’ve averaged 209.29K. According to company’s latest data on outstanding shares, there are 30.14 million shares outstanding.
Nearly 34.12% of AN2 Therapeutics Inc’s shares belong to company insiders and institutional investors own 36.69% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 33176.0 shares as on 2025-05-30, resulting in a short ratio of 0.11. According to the data, the short interest in AN2 Therapeutics Inc (ANTX) stood at 18.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 36054.0. The stock has fallen by -20.29% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ANTX stock heading into the next quarter.
